High activity Rhenium-186 HEDP with stem cell rescue in prostate cancer
Author Information
Author(s): O'Sullivan J M, McCready V R, Flux G, Norman A R, Buffa F M, Chittenden S, Guy M, Pomeroy K, Cook G, Gadd J, Treleaven J, Al-Deen A, Horwich A, Huddart R A, Dearnaley D P
Primary Institution: Royal Marsden NHS Trust
Hypothesis
Can high activities of Rhenium-186 HEDP with peripheral blood stem cell rescue be safely administered to patients with hormone refractory prostate cancer metastatic to bone?
Conclusion
The study demonstrated that administering 5000 MBq of Rhenium-186 HEDP is feasible and can lead to significant PSA responses in some patients.
Supporting Evidence
- Twenty-five patients received Rhenium-186 HEDP treatment.
- 20% of patients had a PSA reduction of 50% or more.
- The main toxicity observed was thrombocytopaenia.
- Actuarial survival at 1 year was 54%.
- Patients experienced a maximum of 4 days as inpatients for radioprotection.
Takeaway
Doctors tested a new treatment for prostate cancer that uses a special radioactive substance and stem cells to help patients feel better. It worked for some patients, helping them live longer.
Methodology
Patients received Rhenium-186 HEDP followed by stem cell rescue, with monitoring of toxicity and PSA response.
Limitations
The study was limited by a small sample size and the short follow-up period.
Participant Demographics
Median age was 64 years, with a range of 50 to 73 years; all had hormone refractory prostate cancer with bone metastases.
Statistical Information
P-Value
0.015
Confidence Interval
95% CI 29.5–73.3%
Statistical Significance
p=0.015
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website